New research in #DADM highlight @altoida NeuroMarker, a 10-minute self-administered digital cognitive assessment.
Findings support individuals identified as cognitively impaired were more likely to have elevated plasma pTau217🩸
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Findings support individuals identified as cognitively impaired were more likely to have elevated plasma pTau217🩸
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
October 2, 2026 at 3:49 PM
New research in #DADM highlight @altoida NeuroMarker, a 10-minute self-administered digital cognitive assessment.
Findings support individuals identified as cognitively impaired were more likely to have elevated plasma pTau217🩸
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Findings support individuals identified as cognitively impaired were more likely to have elevated plasma pTau217🩸
alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Circular Genomics, Altoida link AI with blood biomarkers to track Alzheimer's #dementia firstwordhealthtech.com/story/8078947
Loading...
firstwordhealthtech.com
September 23, 2026 at 1:08 AM
Circular Genomics, Altoida link AI with blood biomarkers to track Alzheimer's #dementia firstwordhealthtech.com/story/8078947
Circular Genomics, Altoida Partner for Alzheimer’s Detection, Monitoring
Circular Genomics, Altoida Partner for Alzheimer’s Detection, Drug Development
The firms aim to combine blood-based RNA biomarkers with digital cognitive measures to accelerate Alzheimer's drug development and frontline care.
ebx.sh
September 22, 2026 at 2:45 PM
Circular Genomics, Altoida Partner for Alzheimer’s Detection, Monitoring
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine#USA#San_Diego#Alzheimer's_Disease#Circular_Genomics#Altoida
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine
Discover how Circular Genomics and Altoida's partnership aims to transform Alzheimer's diagnostics by combining cutting-edge biomarkers and AI technology.
third-news.com
September 22, 2026 at 10:06 AM
Collaboration Between Circular Genomics and Altoida to Enhance Alzheimer's Precision Medicine#USA#San_Diego#Alzheimer's_Disease#Circular_Genomics#Altoida
The study is the result of an international collaboration with Altoida, Sant Pau Memory, Hospital Clínic, BBRC & other partners.
🔗 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Research continues to further investigate how cognitive and biological markers can be combined in AD.
🔗 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Research continues to further investigate how cognitive and biological markers can be combined in AD.
A scalable workflow using digital cognitive assessment and pTau217 for MCI detection
INTRODUCTION Blood biomarkers like phosphorylated tau (p-tau)217 offer high diagnostic accuracy for Alzheimer's disease (AD) but face implementation challenges in low-prevalence settings. We evaluat...
alz-journals.onlinelibrary.wiley.com
September 18, 2026 at 9:21 AM
The study is the result of an international collaboration with Altoida, Sant Pau Memory, Hospital Clínic, BBRC & other partners.
🔗 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Research continues to further investigate how cognitive and biological markers can be combined in AD.
🔗 alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
Research continues to further investigate how cognitive and biological markers can be combined in AD.
In 688 participants across Australia, Spain and the US, the Altoida NeuroMarker identified mild cognitive impairment (MCI) with a ROC-AUC of 0.89.
Digitally identified cognitive impairment was also significantly associated with elevated plasma p-tau217.
Digitally identified cognitive impairment was also significantly associated with elevated plasma p-tau217.
September 18, 2026 at 9:21 AM
In 688 participants across Australia, Spain and the US, the Altoida NeuroMarker identified mild cognitive impairment (MCI) with a ROC-AUC of 0.89.
Digitally identified cognitive impairment was also significantly associated with elevated plasma p-tau217.
Digitally identified cognitive impairment was also significantly associated with elevated plasma p-tau217.
*Frontotemporal dementia.
It's different. His father, however, was diagnosed with Alzheimer's in 1991, and died from (likely Alzheimer's-caused aspiration) pneumonia in 1999.
Paternal cousin John Walter died with dementia in 2018.
Maryanne Trump Barry died of cancer in 2023, but had dementia, too.
It's different. His father, however, was diagnosed with Alzheimer's in 1991, and died from (likely Alzheimer's-caused aspiration) pneumonia in 1999.
Paternal cousin John Walter died with dementia in 2018.
Maryanne Trump Barry died of cancer in 2023, but had dementia, too.
How Is Frontotemporal Dementia Different From Alzheimer's - Altoida
The key differences between frontotemporal dementia and Alzheimer’s disease are the impacted brain regions, early-stage symptoms, and age at diagnosis.
altoida.com
May 10, 2026 at 5:16 AM
*Frontotemporal dementia.
It's different. His father, however, was diagnosed with Alzheimer's in 1991, and died from (likely Alzheimer's-caused aspiration) pneumonia in 1999.
Paternal cousin John Walter died with dementia in 2018.
Maryanne Trump Barry died of cancer in 2023, but had dementia, too.
It's different. His father, however, was diagnosed with Alzheimer's in 1991, and died from (likely Alzheimer's-caused aspiration) pneumonia in 1999.
Paternal cousin John Walter died with dementia in 2018.
Maryanne Trump Barry died of cancer in 2023, but had dementia, too.
Signal or noise? > Digital Biomarkers Global Markets Report 2025-2030 with
Profiles of Leading Players – Actigraph, AliveCor, Altoida,
Evidation Health, and IXICO – ResearchAndMarkets.com >> Comment below! #AI #mhealth #IoT #healthtech #industry40
Profiles of Leading Players – Actigraph, AliveCor, Altoida,
Evidation Health, and IXICO – ResearchAndMarkets.com >> Comment below! #AI #mhealth #IoT #healthtech #industry40
Digital Biomarkers Global Markets Report 2025-2030 with
Profiles of Leading Players – Actigraph, AliveCor, Altoida,
Evidation Health, and IXICO – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Digital Biomarkers: Global Markets” report has been added to ResearchAndMarkets.com’s offering. The global market for digital biomarkers is estimated to grow from $5 billion in 2025 to $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 30.4% from 2025 through 2030. This report provides an overview of …
dlvr.it
September 1, 2025 at 7:33 PM
Signal or noise? > Digital Biomarkers Global Markets Report 2025-2030 with
Profiles of Leading Players – Actigraph, AliveCor, Altoida,
Evidation Health, and IXICO – ResearchAndMarkets.com >> Comment below! #AI #mhealth #IoT #healthtech #industry40
Profiles of Leading Players – Actigraph, AliveCor, Altoida,
Evidation Health, and IXICO – ResearchAndMarkets.com >> Comment below! #AI #mhealth #IoT #healthtech #industry40
There's a suite of new AI-powered digital cognitive tests coming to market.
The goal: Speed up the assessment and spot people who might benefit from more extensive testing sooner.
My latest for @beingpatient.bsky.social
beingpatient.com/digital-cogn...
The goal: Speed up the assessment and spot people who might benefit from more extensive testing sooner.
My latest for @beingpatient.bsky.social
beingpatient.com/digital-cogn...
Digital Cognitive Tests: How AI Tools Could Transform Alzheimer's Diagnosis and Care | Being Patient
AI-powered digital cognitive tests like Cognivue, Linus Health, and Altoida aim to detect early dementia and speed up Alzheimer’s diagnosis.
beingpatient.com
August 29, 2025 at 6:32 PM
There's a suite of new AI-powered digital cognitive tests coming to market.
The goal: Speed up the assessment and spot people who might benefit from more extensive testing sooner.
My latest for @beingpatient.bsky.social
beingpatient.com/digital-cogn...
The goal: Speed up the assessment and spot people who might benefit from more extensive testing sooner.
My latest for @beingpatient.bsky.social
beingpatient.com/digital-cogn...
Digital Cognitive Tests: How AI Tools Could Transform Alzheimer’s Diagnosis and Care beingpatient.com/digital-cogn... by @spichaksimon.bsky.social @beingpatient.bsky.social
#Alzheimers #dementia #AI #ArtificialIntelligence
#Alzheimers #dementia #AI #ArtificialIntelligence
Digital Cognitive Tests: How AI Tools Could Transform Alzheimer's Diagnosis and Care | Being Patient
AI-powered digital cognitive tests like Cognivue, Linus Health, and Altoida aim to detect early dementia and speed up Alzheimer’s diagnosis.
beingpatient.com
August 27, 2025 at 8:39 PM
Digital Cognitive Tests: How AI Tools Could Transform Alzheimer’s Diagnosis and Care beingpatient.com/digital-cogn... by @spichaksimon.bsky.social @beingpatient.bsky.social
#Alzheimers #dementia #AI #ArtificialIntelligence
#Alzheimers #dementia #AI #ArtificialIntelligence
🚀 Digital Neuro Biomarkers Market to hit $4B by 2032 from $706M in 2024 (CAGR 24.2%)! Wearables + AI = smarter neurology. 📊🧠 Top players: NeuraLight, Altoida, Qiagen.
Read more: www.credenceresearch.com/report/digit...
#NeuroTech #Biomarkers #DigitalHealth #AIinHealthcare
Read more: www.credenceresearch.com/report/digit...
#NeuroTech #Biomarkers #DigitalHealth #AIinHealthcare
April 8, 2025 at 7:34 AM
🚀 Digital Neuro Biomarkers Market to hit $4B by 2032 from $706M in 2024 (CAGR 24.2%)! Wearables + AI = smarter neurology. 📊🧠 Top players: NeuraLight, Altoida, Qiagen.
Read more: www.credenceresearch.com/report/digit...
#NeuroTech #Biomarkers #DigitalHealth #AIinHealthcare
Read more: www.credenceresearch.com/report/digit...
#NeuroTech #Biomarkers #DigitalHealth #AIinHealthcare